Virica Biotech, Oxford Biomedica Enter R&D Partnership

To improve the manufacturing of lentiviral vector gene therapies using viral sensitizers.

Virica Biotech, a developer of solutions for scaling of viral medicines, is collaborating with Oxford Biomedica to improve the yield and production efficiency of Oxford’s next generation lentiviral vector gene therapies using Virica’s Viral Sensitizers (VSEs).

“There is growing demand from major industry players to use leading lentivirus technologies, like Oxford Biomedica’s LentiVector platform, to develop cell and gene therapies,” said Ella Korets-Smith, chief business officer, Virica Biotech. “We envision our VSEs as an ideal solution in their quest to pursue new ways to increase commercial yields in order to support the use of life-saving cell and gene therapies globally.”

Oxford Biomedica is a pioneer of cell and gene therapies. Its LentiVector platform enables the successful development of breakthrough gene and cell-based medicines, and through collaborations with pharmaceutical partners, has delivered the first FDA and ema approved CAR-T cell therapy .